Company

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031
NASDAQ: REGNRegeneron Pharmaceuticals

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC
ADC / XDCClinical trial approval / initiation

Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler
BiotechChance Pharmaceuticals

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform
Cell-therapyNYSE: TAK

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform

Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening
CancerHKG: 2629

Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening

Show More